Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-421 plus Chidamide for HIV Reservoir Reduction
NCT04985890Phase 2Not yet recruiting
- Sponsor
- United BioPharma
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- IgG Antibodies
01
Overview
Phase 2, randomised, open-label trial of semzuvolimab in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by United BioPharma. Primary endpoint: HIV-1 Total DNA levels at 48 weeks. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
semzuvolimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04985890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985890.